Temps réel
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
98 EUR | -1,01% | -.--% | +2,08% |
CA 2024 * | 42,81 Md 39,75 Md 38,78 Md | CA 2025 * | 52,47 Md 48,72 Md 47,53 Md | Capitalisation | 684 Md 635 Md 620 Md |
---|---|---|---|---|---|
Résultat net 2024 * | 11,93 Md 11,08 Md 10,81 Md | Résultat net 2025 * | 16,55 Md 15,37 Md 15 Md | VE / CA 2024 * | 16,5 x |
Dette nette 2024 * | 19,98 Md 18,55 Md 18,1 Md | Dette nette 2025 * | 15,29 Md 14,19 Md 13,85 Md | VE / CA 2025 * | 13,3 x |
PER 2024 * |
56,8
x | PER 2025 * |
40,9
x | Employés | - |
Rendement 2024 * |
0,68% | Rendement 2025 * |
0,79% | Flottant | 99,8% |
Dernier transcript sur Eli Lilly and Company
1 jour | -1,01% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01/01/01 |
Ruth Gimeno
PSD | President | - | - |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Director/Board Member | 63 | 25/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/04/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/01/05 |
Nom | PEA | Position | Varia. 1 janv. | Notation |
---|---|---|---|---|
BGF WORLD HEALTHSCIENCE A2 | Non | 0.88M USD | -2,00% | |
BELFIUS EQUITIES GLOB HEALTH CARE C$ CAP | Non | 34.48M USD | -3,00% | |
ABRDN GLB SUS EQ A ACC USD | Non | 8.16M USD | +10,00% | |
BGF US GROWTH A2 | Non | 212.94M USD | +46,00% | |
BGF US SUSTAINABLE EQUITY ZI2 USD | Non | 0.58M USD | 0,00% |
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+26,51% | 568 Md | |
-4,36% | 361 Md | |
+19,30% | 330 Md | |
+3,73% | 283 Md | |
+16,70% | 239 Md | |
+8,78% | 204 Md | |
-7,93% | 198 Md | |
+7,68% | 168 Md | |
-2,71% | 160 Md |
- Bourse
- Actions
- Action LLY
- Action LLY